Why the study?
Does perioperative sublingual isosorbide dinitrate prevent cardiovascular morbidity and mortality in patients with known or suspected atherosclerotic coronary artery disease undergoing noncardiac surgery?
Does perioperative sublingual isosorbide dinitrate prevent cardiovascular morbidity and mortality in patients with known or suspected atherosclerotic coronary artery disease undergoing noncardiac surgery?
Perioperative administration of sublingual isosorbide dinitrate is associated with a very low rate of cardiovascular complications in patients with coronary artery disease undergoing noncardiac surgery.
Answers are grounded in this paper and cite their sources.
Should not yet change practice; hypothesis-generating for perioperative sublingual isosorbide dinitrate in coronary disease.
One hundred fifty-two consecutive patients with a known or suspected diagnosis of atherosclerotic coronary artery disease were administered 5 mg sublingual isosorbide dinitrate 2 hours and (1/2) hour preoperatively and every 4 hours postoperatively for 3 days, for the prevention of cardiovascular morbidity and mortality, which could result from various noncardiac surgical procedures; 125 patients received general anesthesia. Cardiovascular complications occurred in 3 patients (1.9%). Two patients did not enter the study, owing to side effects of the medication (1.3%). The complications were 1 each (0.6%) of the following: atrial fibrillation, hypotension, and cardiac arrest. Mortality was 0%. These results are exceptionally favorable when compared to the average cardiovascular morbidity rate of 2.8% to 49% in patients assigned to various risk stratifications in the medical literature.
No takes yet. Share an insight, caveat, or question.
Basil M. RuDusky (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: